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Executive Summary
Recently controversy has surrounded the issue of whether Social Security
payments to the elderly should continue to be adjusted automatically accord-
ing to changes in the Consumer Price Index (CPI). One issue in the public
policy debate concerns whether price inflation is different for the elderly,
particularly because the official Bureau of Labor Statistics price indexes for
medical care have been growing more rapidly than the overall CPI, and
medical care expenditures constitute a larger proportion of the elderly's budget
than of the young's.
Using annual IMS data from 1990 to 1996, we examine empirically whether
elderly-nonelderly price inflation differentials exist for prescription pharma-
ceuticals. We assess prices for prescription drugs destined for ultimate use by
the elderly versus the nonelderly at three points in the distribution chain:
initial sales from manufacturers, intermediate purchases by retail pharmacies,
and final sales from retail pharmacies to patients or payors. We find that at the
initial point in the distribution chain, no differences in price inflation exist for
the aggregate of drugs destined for use by the elderly versus those for the
nonelderly. At the intermediate sell-in point to pharmacy distribution, we
examine antibiotics (ABs), antidepressants (ADs), and calcium channel block-
ers (CCBs). For ABs, since 1992 price inflation has been somewhat greater for
the elderly than for the young, reflecting in part the elderly's more intensive
use of newer branded products having fewer side effects, adverse drug inter-
actions and more convenient dosingattributes of particular importance to
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the elderly. For ADs, price inflation is considerably less for the elderly than for
the young, due in large part to the elderly's greater use of older generic
products. For CCBs, elderly-nonelderly differentials are negligible. None of
these differentials adjust for variations in quality.
At the final retail sell-out point, we examine only ADs. We find that because
retailers obtain larger gross margins on generic than on branded products, and
because the elderly are disproportionately large users of generic ADs, the
elderly-nonelderly price inflation differential benefiting the elderly at the
intermediate point is reduced considerably at final sale.
I.Introduction
Over the next few decades, the U.S. population aged 65 and older wifi
grow both in absolute numbers and as a share of the total population.
As people age, they tend to have higher medical care expenses. Thus
an increasingly elderly society can be expected to devote a greater
amount of its expenditures to medical care. The implications of a
graying society for future medical care expenditures depend of course
on both the price and the quantity of future medical care for the
elderly.
To the extent that they live on fixed incomes, the elderly are particu-
larly vulnerable to price inflation. Moreover, medical care price in-
creases are likely to affect the elderly differentially, because medical
care is a larger share of their current budgets. Recently there has been
substantial controversy concerning the continued automatic adjust-
ment of Social Security payments to the elderly on the basis of changes
in the Consumer Price Index (CPI). A panel of experts estimates that
the CPI overstates true cost-of-living increases by about 1.1% per year
(U.S. Senate Finance Committee 1996).
Relatively little is known about the extent to which price inflation of
the basket of medical care goods and services used by the elderly
differs from the price inflation of the set of medical care goods and
services used by younger Americans. In this chapter, we focus on
elderly-nonelderly price inflation differentials for one component of
medical care, namely, prescription pharmaceuticals, from 1990 to
1996.1
The systems by which prescription pharmaceuticals are distributed
and paid for in the United States are complex and rapidly changing.
1. For a discussion of patterns in total acute care health expenditures by patient age
group from 1953 to 1987, see Cutler and Meara 1997.Is Price Inflation Different for the Elderly? 35
We assess elderly-nonelderly price differentials at three different
points in the distribution chain: (I) the initial point involving sales
from manufacturers to wholesalers, retailers, and hospitals; (2) an
intermediate point at which retail pharmacies acquire prescription
drugs from wholesalers and manufacturers; and (3) a final point at
which retail pharmacies dispense and sell prescription drugs to pa-
tients. With respect to payors, at the retail sell-out point in the distri-
bution chain, we distinguish consumers' out-of-pocket expenditures
for pharmaceuticals from those expenditures involving government
funds (Medicaid and various public assistance programs) as well as
from payments by private, third-party insurance sources (fee-for-serv-
ice insurance plans and various forms of "medigap" and managed
care).
One potential reason for elderly-nonelderly drug price inflation
differentials is that the brand-generic proportions could vary by age.
For treatment of acute conditions, the elderly may be more fragile, and
thus prudent medical practice might suggest prescribing for them the
newest generation of drugs having the fewest side effects and adverse
drug interactions and the most convenient dosing. Under this hypothe-
sis, for certain acute conditions, one might expect the elderly to use
newer, branded drugs disproportionately. To the extent newer,
branded drugs increase in price more rapidly than older, off-patent
and generic drugs, the elderly's bundle of drugs would be expected to
increase more rapidly than that of the young.
Although the same considerations would apply for treatment of
chronic conditions, the surviving elderly are more likely to be using
older drug products, for physicians are hesitant to change medications
when a particular existing drug regimen is working well in treating a
chronic condition. Because they have stickier usage patterns and have
survived to old age, the elderly would therefore disproportionately use
older drugs, which are more often available as generics, to treat their
chronic conditions. Under this hypothesis, drug price inflation for the
elderly's bundle would be less than that for the young. We examine
both these hypotheses empirically, focusing on three therapeutic
classesantibiotics, antidepressants and calcium channel blockers.
We begin in the next section by providing background information
on various trends and demographic aspects of the U.S. medical care
marketplace and summarizing the literature dealing with age differ-
entials in the rate of health care price inflation. In Sections III, IV, and
V we focus on prices at initial, intermediate, and final links of the36 Berndt, Cockburn, Cocks, Epstein, and Griliches
distribution chain, respectively. We document and then examine im-
plications of the fact that the elderly and nonelderly have differential
uses of drugs across various therapeutic classes, and varying brand-
generic consumption patterns within therapeutic classes. We compute
and report on separate elderly-nonelderly price indexes, using a fixed-
weight Laspeyres index that mimics procedures currently employed
by the U.S. Bureau of Labor Statistics (BLS), and also employ a chang-
ing-share Divisia price index recommended for use by the CPI com-
mission. We also comment on the important role of differential
brand-generic gross margins at retail pharmacies. In section VI we




We begin by reviewing recent changes in the components, sources,
location, and methods of payment for health care items with a particu-
lar focus on pharmaceuticals. In 1995, prescription drugs accounted for
6.3% of the $878.8 billion in total personal health expenditures, nonpre-
scription drugs constituted 3.2%, professional medical services 34.1%,
hospital care 39.8%, nursing home care 8.9%, home health care 3.3%,
and supplies and other, the remaining 44%2
The sources of funds for personal health expenditures varied consid-
erably. Whereas consumers' out-of-pocket expenditures accounted for
18.3% of expenditures for physician services, 3.3% of those for hospital
care, and 42.4% of those for nursing home care, direct consumer
expenditures (including copayments and deductibles) constituted
39.5% of total prescription drug spending, down from 48.3% in 1990;
private third-party insurance covered 39.8% of total prescription drug
spending in 1994, up from 34.5% in 1990.
The locus of prescription pharmaceutical sales is also undergoing
change. In 1996, for example, about 57% of the money spent on phar-
maceuticals involved retail sales (chain pharmacies, independents,
mass merchandisers, and food stores), down from 64% in 1990.
Statistics in this and the following paragraph are taken from Levit et al. 1996, Table 1
(p. 179), Table 5 (p. 185), Table 12 (p. 206), Table 13 (p. 207), and Table 14 (p. 208).
In 1995 (1990), the portion of total prescription drug spending from governmental
sources was 20.7% (17.0%).Is Price Inflation Different for the Elderly? 37
Whereas the dollar share for mail order increased from 5% to 9%, that
for hospitals, clinics, and nursing homes remained relatively constant,
28% in 1990 and 29% in 1996, as did that for staff model health
maintenance organizations (HMOs)-2% in both years.4
Within the retail sector, method of payment has changed dramati-
cally over the last several years. As table 2.1 shows, since 1991 the share
of new prescriptions paid for by cash has fallen sharply from 59% to
32%, whereas that paid for directly by third-party sources other than
Medicaid has doubled, increasing from 28% to 57%. Third-party insur-
ance has now become the predominant method of payment for pre-
scription pharmaceuticals sold in retail outlets. The Medicaid share of
dollars has varied less, from a high of about 15% in 1993 to about 11%
in 1996. (Note that Medicare does not cover outpatient pharmaceutical
expenses.) In terms of numbers of new prescriptions, the 1990-96
average annual growth rate (AAGR) for cash customers is -6.6% vs.
20.5% for third-party payors.
The above discussion on health expenditures does not distinguish
by age group. Through its annual Consumer Expenditure Survey
(CES), the BLS collects data on consumers' out-of-pocket expenditures
(OOPs) for various budget items, including components of health care.
The CES's unit of observation is the consumer unit ("household"),
defined as "the person/group of persons in the household who is/are
independent of all other persons in the household for payment of their
major expenses" (U.S. Department of Commerce 1994, 3). The person
in the consumer unit (CU) with major financial responsibility for
payment of housing expenses is called the reference person ("head of
household") of the consumer unit. CUs are stratified in a number of
ways, including one of particular interest to us, namely, by age of the
reference person. In tables 2.2 and 2.3 we summarize data from the
1990 and 1995 CES. Five points are particularly worth noting.
First, as one would expect, older Americans tend to have larger
OOPs on medical care items and services than do the younger. The
OOPs per CU health expenditure share generally grows with age, but
it increases particularly sharply after age 65, as the top three panels of
table 2.2 show. In 1995, for example, total OOP health-related expen-
ditures for those under age 25 averaged $465, for those aged 55-64 it
was $1,909, and for those 75 and over the average was $2,683. Whereas
the average share of health care expenditures over all consumer units
4. IMS 1996 Class of Trade Analysis and Retail Method of Payment Analysis.38 Berndt, Cockburn, Cocks, Epstein, and Griliches
Table 2.1
Retail methods of payment, 1991-1996
Source: IMS America 1996.
Date








3Q91 262.4 59.3 122.2 443.9 59.1% 13.4% 27.5%
4Q91 279.2 66.8 136.3 482.3 57.9% 13.9% 28.3%
1Q92 268.6 67.5 140.9 477.0 56.3% 14.2% 29.5%
2Q92 262.5 65.3 140.9 468.7 56.0% 13.9% 30.1%
3Q92 254.0 65.8 137.1 456.9 55.6% 14.4% 30.0%
4Q92 268.2 72.0 151.9 492.1 54.5% 14.6% 30.9%
1Q93 259.1 74.4 165.2 498.7 52.0% 14.9% 33.1%
2Q93 247.0 71.1 164.8 482.9 51.1% 14.7% 34.2%
3Q93 233.5 69.5 164.0 467.0 50.0% 14.9% 35.1%
4Q93 250.1 76.3 186.4 512.848.8% 14.9% 36.3%
1Q94 232.4 69.5 201.4 503.3 46.2% 13.8% 40.0%
2Q94 225.2 67.5 205.9 498.6 45.2% 13.5% 41.3%
3Q94 215.5 63.4 205.4 484.3 44.5%13.1% 42.4%
4Q94 222.2 66.7 229.0 517.9 42.9%12.9% 44.2%
1Q95 213.9 70.6 251.7 536.2 39.9% 13.2% 46.9%
2Q95 200.5 66.1 252.0 518.6 38.7% 12.7% 48.6%
3Q95 192.7 63.9 251.9 508.5 37.9% 12.6% 49.5%
4Q95 199.8 68.2 282.2 550.2 36.3% 12.4% 51.3%
1Q96 192.8 67.6 291.8 552.2 34.9% 12.2% 52.8%
2Q96 180.0 61.5 294.2 535.7 33.6% 11.5% 54.9%
3Q96 176.6 60.3 296.3 533.2 33.1% 11.3% 55.5%
4Q96 183.6 65.7 325.5 574.8 31.9% 11.4% 56.6%
AAGR-6.6%2.0% 20.5% 5.0%Is Price Inflation Different for the Elderly? 39
in 1995 was 5.4%, for those under age 25 it was 2.5%, between ages 55
and 64 it was 5.9%, for those 65 and over it doubled to 11.9%, and for
those 75 and over it increased further to 14.4%. Moreover, the data in
table 2.2 reveal that the share of health care expenditures attributable
to each age group was quite stable over 1990-95.
Second, as the elderly constitute a greater proportion of the popula-
tion, they account for an increasingly large and disproportionate per-
centage of the nation's total OOP health expenditures. As shown in the
bottom three panels of table 2.2, whereas CUs over age 65 accounted
for 20.7% of all consumer units in 1990, their larger per capita out-of-
pocket health expenditures implied that the CUs over age 65 consti-
tuted 30.9% of OOP health expenditures over all age groups; by 1995,
these numbers increased slightly to 21.1% and 32.3%, respectively.6
Interestingly, the proportion of consumer units aged 65-74 decreased
very slightly between 1990 and 1995, from 11.7% to 11.6%, but the
percentage of consumer units aged 75 and over increased more
sharply, from 9.0% to 9.6%, resulting in an increase in their OOP health
expenditures share over all age groups from 13.5% to 14.8%.
Third, although total OOPs health care expenditure patterns may be
stable, since 1990 people of all ages (and especially the elderly) appear
to have significantly substituted payments to health insurance for
direct payments for professional medical services, drugs, and medical
supplies.7 Note that in the CES, consumer OOP expenditures for health
insurance are the sum of employees' pretax contributions at work and
direct health insurance premium payments, but employers' health
insurance contributions are not included, for those are treated as a
business expense. As the second panel of table 2.3 shows, for all
consumers the health insurance share increased from 39% to 50%
between 1990 and 1995. For those under age 65, the 1995 health
insurance share was about 45%, up from slightly under 40% in 1990;
for the elderly, however, the increase was even greater, from 45% in
1990 to 58% in 1995. Thus by 1995 more than half of the elderly's OOPs
health care budget was devoted to health insurance.
For comparisons back to 1980, see Acs and Sabeihaus 1995.
Note that these OOPs exclude all government funding, such as that for Medicare.
Thus the 32% figure likely understates the elderly's proportion of total OOPs plus
government health care expenditures.
Employers may also be shifting health insurance premium costs and copayments/




































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































142 Berndt, Cockburn, Cocks, Epstein, and Grifiches
Fourth, in a related development, the professional medical services
component of OOP expenditures has fallen sharply since 1990, as
insurers presumably have borne a greater share. In 1990, for example,
the average expenditure on medical services by those aged 65 and over
was $664, but by 1995 this had fallen 28% to $479. For all consumers,
the medical service expenditure share fell from 38% to 30%, but for
those 65 and over the drop was even larger, from 30% in 1990 to 18%
in 1995.
Fifth, for drugs (the CES data include both prescription and over-
the-counter nonprescription drug expenditures), in both 1990 and 1995
expenditures increased with age and were about twice as large for the
elderly relative to all consumers. The level of OOP expenditures in-
creased about 11% for all consumers from 1990 to 1995 ($252 to $280),
but for the elderly, the OOPs increase was larger, about 14-15% ($475
to $544). In terms of expenditure shares, the drug component fell
slightly, from 17% to 16% for all consumers, presumably reflecting a
shift to payments by health insurers. For those 75 and over, the drop
in the drug component of OOPs was slightly larger, from 22.5% in 1990
to 20.7% in 1995.
In summary, the CES data indicate that the composition of OOPs has
changed considerably since 1990, and in different ways for the elderly
versus the nonelderly. A dominant trend for people of all ages, how-
ever, is away from direct out-of-pocket payments for medical services,
drugs, and medical supplies and instead toward health insurance. To
the extent that this growth in health insurance results in greater buying
power by agents of consumers relative to that of providers andsuppli-
ers, and to the extent any resulting lower provider-supplier prices are
passed on to consumers in the form of lower health insurance premi-
ums, this shift could result in benefits to consumers,particularly the
elderly.
Medical Prices: Entire U.S. Population
Expenditures are by definition the product of price times quantity.
Disaggregating the growth of health expenditures into price and quan-
tity components involves many conceptual and practical difficulties.8
The BLS publishes an aggregate medical care Consumer Price Index
(MCPI) as well as price indexes for various of the MCPI components,
such as prescription drugs, professional medical services, and hospital
8. For an overview discussion, see Triplett 1997 and Getzen 1992.Is Price Inflation Different for the Elderly? 43
Table 2.4
Price inflation in the overall CPI and in the Medical CPI, 1927-1996, average annual growth
rates
However, in constructing the BLS's MCPI, the out-of-pocket payments for health
insurance are in turn distributed into payments by insurers for medical services, medical
commodities, and health insurers' retained earnings. See Fixler 1996, Daugherty 1964,
Ford and Sturm 1988, and Getzen 1992.
United States Department of Labor, Bureau of Labor Statistics, 1996, CPI Detailed
Report, Tables 1 and 3 (CPI for All Urban Consumers).
For several years in 1927-46, however, year-to-year changes in the CPI were greater
than for the MCPI. See Getzen 1992 for a discussion.
Time period CPI-Urban Medical CPI Ratio MCPI/CPI
1927-46 0.60% 1.03% 1.72
1946-56 3.38% 4.22% 1.25
1956-66 1.76% 3.36% 1.91
1966-76 5.79% 7.05% 1.22
1976-86 6.78% 8.90% 1.31
1986-96 3.65% 6.46% 1.77
1927-96 3.24% 4.59% 1.42
Sources: U.S. Department of Labor, Bureau of Labor Statistics. For the MCPI prior to 1935,
Langford 1957, Table 1, p. 1055.
and related services. Each of these price indexes is based on consumers'
OOPs and thereby excludes all payments by governments and third-
party insurers.9
Recent MCPI data show that prices consumers pay for medical care
have been increasing more rapidly than those for other items. Indexed
to 100 in 1990, the 1996 MCPI was 140.2, for prescription drugs it was
133.7, for nonprescription drugs and medical supplies 118.7, for phy-
sicians' services 134.6, and for hospital and related services 151.4,
whereas the CPI for all items was only 120.0.10 Thus, except for non-
prescription drugs, prices of health-related items and services gener-
ally appear to have risen more rapidly than the overall CPI. Moreover,
as table 2.4 shows, this more rapid increase of the MCPI relative to the
CPI is not a recent phenomenon. Since 1927, the first year for which
MCPI data are available, medical inflation has generally been greater
than that of all goods and servicesY' Over the entire 1927-96 time
period, the MCPI has risen at an AAGR of 4.59%, more than 40% above
the 3.24% for the overall CPI.
In its recent report to the U.S. Senate Finance Committee (1996),
however, the CPI commission concluded that the MCPI was substan-
tially upward biased, stating that ". .healthcare inflation is seriously44 Berndt, Cockburn, Cocks, Epstein, and Griliches
overstated because of the substantial uncounted quality change" (72,
footnote 71), such as improvements in outcomes (60; see also Shapiro
and Wilcox 1996). Specifically, the commission estimated that the up-
ward bias of the MCPI is 3% per year for prescription drugs, for
professional medical services, and for hospital and related services,
and 1% for nonprescription drugs (58-62). Moreover, the commission
recommended major changes in the BLS's treatment of health insur-
ance expenditures (iv). Currently the BLS's procedures for the health
insurance component do not take changing coverages into account, but
instead simply multiply a medical care price index by an index of
health insurance ex post retained earnings, that is, the ratio determined
by health insurance revenues minus health insurance payments, all
divided by health insurance revenues (Lane 1996, 22; see also refer-
ences in note 9).
The BLS also publishes producer price indexes (PPIs) for various
industries, focusing on the initial point in the distribution chain, where
it "measures average changes in selling prices received by domestic
producers for their output" (U.S. Department of Labor, Bureau of
Labor Statistics 1992, 140). Although the BLS has published PPIs for
certain health-related industries such as prescription pharmaceuticals
for many years, currently there is no overall medical care PPI. Recently,
however, the BLS introduced separate PPIs for offices and clinics of
doctors of medicine (December 1993), skilled and intermediate care
facilities (December 1994), general medical and surgical hospitals (De-
cember 1992), psychiatric hospitals (December 1992), and medical labo-
ratories (June 1994). A number of recent research studies report that
for pharmaceuticals, the PPI overstates price inflation considerably.12
Studies by Cutler et al. (1996) on the treatment of heart attacks and by
Shapiro and Wilcox (1996) on cataract surgery also suggest substantial
upward bias in medical-related PPIs. Cutler et al. point out that appar-
ent price inflation actually involves frequent substitution of more
expensive but also more effective inputs.
Medical Prices: Focus on the Elderly
Larger medical-related expenditure weights for the elderly than for the
young combined with apparent greater price inflation for medical care
items than for the overall CPI has created an impression that the
12. See, for example, Berndt, Griliches, and Rosett 1993, Griliches and Cockburn 1994,
and Bemdt, Cockburn, and Grifiches 1996.Is Price Inflation Different for the Elderly? 45
relatively large price increases involving health care items and services
in the last decade have adversely affected the elderly in particular.
Indeed, such considerations played a prominent role in the recent
debate concerning a possible downward adjustment of the CPI to
index Social Security benefits for the elderly.13 As noted earlier, how-
ever, the greater growth of the MCPI than for the CPI goes back at least
to 1927. Hence, for the many years when today's elderly were younger,
they too benefited from inflation that was less burdensome for them
than for the elderly of their time. Over the entire life cycle, it is not at
all clear whether today's elderly cohort is relatively better or worse off
than earlier or future elderly cohorts. With this caveat in mind, along
with the understanding that growth in the MCPI may be overstated
because of overlooked quality improvements, we now briefly summa-
rize the existing literature on separate price indexes for the elderly.14
Anticipating that the introduction of Medicare in July 1966 might
have an impact on medical care prices in summer 1965 the Social
Security Administration arranged with the BLS to collect supplemen-
tary prices for three surgical procedurescholecystectomy (removal of
gall bladder), prostatectomy (removal of prostate gland), and fractured
neck of femur (hip surgery)and two in-hospital medical services
acute myocardial infarction (treatment of heart attack) and cerebral
hemorrhage (stroke)that were particularly important to older per-
sons, though not necessarily limited to them. A report to the President,
summarized by Rice and Horowitz (1967, based on U.S. Department
of Health, Education, and Welfare 1967), concluded that "[t]he index
of the five in-hospital surgical and medical procedures particularly
significant for the aged did not increase as rapidly during 1966 as the
combined index for physicians' fees regularly priced for the CPI"
(28).15
More recently, in response to a mandate from 1987 amendments to
the Older Americans Act of 1965, the BLS created an experimental
price index for elderly consumers (CPI-E). The CPI-E employs differ-
ential expenditure weights for the elderly (defined as ages 62 and over)
See, for example, Kuttner 1997 and Gephardt 1997.
For a review of literature on various BLS experimental price indexes, including a
separate price index for the poor, both old and young, see Garner et al. 1996 and
Moulton-Stewart 1997.
Rice and Horowitz (1967, 25) report that the December 1965December 1966 price
index growth rates ranged from 2.5% for cholecystectomy to 6.9% for prostatectomy,
whereas the combined index for physicians' fees regularly priced for the CPI increased
7.8%.46 Berndt, Cockburn, Cocks, Epstein, and Grifiches
and nonelderly, based on CES data, but assumes that within each
category weight, the distribution of prices, the outlets from which
consumers buy, the use of coupons and availability of discounts, as
well as the quality of the items purchased, are the same for the elderly
and the nonelderly.16 From 1982 through 1996, the CPI-E for the elderly
rose 67.9%, while the CPI rose 62.5%, implying that over the entire
fourteen-year time span, the CPI had an AAGR of 3.53%, while the
CPI-E for the elderly grew at a slightly larger 3.77% per year.17 The
larger health care expenditure weights for the elderly, along with
greater measured medical price inflation, account almost entirely for
the difference in AAGRs. As noted by the CPI commission, however,
medical care prices are likely to have overstated inflation by not fully
accounting for improvements in quality. If this is correct, then as
Moulton and Stewart (1997) note, "A reduced rate of inflation for
medical care would mitigate and perhaps eliminate any difference
between the CPI-E and the official CPIs" (21).
A related recent study by Garner, Johnson, and Kokoski (1996)
focuses on experimental price indexes for the poor, based on several
alternative definitions of "poor." Using CES data for weights, along
with CPI prices from 1984 to 1994, they find "very little difference
between the experimental consumer price indexes produced for the
poor and the corresponding CPI for the whole sample" (33). Similarly,
Rubin and Koelin (1996), examining real income growth and expendi-
tures on necessities for a variety of demographic groups from 1980 to
1990, conclude that
for the population in general, well-being increased over the 1980s, as
measured by both real income and discretionary spending. The well-being of
elderly households increased relatively more than that of nonelderly house-
holds, and the well-being of recipients of cash assistance increased relatively
less than that of those who did not receive assistance.18 (P. 30)
In summarizing their findings concerning differential rates of price
growth experienced by diverse groups in the population, the CPI
commission stated:
Some have suggested that different groups in the population are likely to have
faster or slower growth in their cost of living than recorded by changes in the
See Garner, Johnson, and Kokoski 1996, 37, and Moulton and Stewart 1997, 18. The
time costs of shopping could also differ for the elderly.
See Amble and Stewart 1994 and Mason 1988. The overall CPI refers to the CPI-All
Urban Consumers index.
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CPI. We find no compelling evidence of this to date.. .. Further work onthis
subject remains to be done. In particular, the prices actually paid, not just
expenditure shares, may differ. (U.S. Senate Finance Committee 1996, 72)
With this information and brief overview of related literature as
background, we now turn to a discussion of our own new research. In
section III we focus on drug prices at the first point in the distribution
chain, from producers to wholesalers, hospitals, and retailers.19 In
section IV we examine an intermediate point, namely, the acquisition
prices retail pharmacies pay to wholesalers and manufacturers. Then
in section V we assess prices at final points in the distribution chain,
from retail pharmacies to patients and payors. Because of data limita-
tions, we do not examine prices received by mail order pharmacies,
which account for roughly 9% of total prescription dollar sales.
III. Producers' Prices for Drugs Destined for Use by Old versus
Young
In reporting on prices at the first point in the distribution chain from
manufacturers to wholesalers and retailers, the BLS publishes monthly
PPIs for about fifty therapeutic classes of prescription pharmaceuticals,
such as analgesics, broad- and medium-spectrum antibiotics, cancer
therapy products, cardiovascular therapy products, antidepressants,
and vitamins. Prices in these various therapeutic classes have increased
at different rates. Since 1981, PPIs for anticoagulants, antiarthritics, and
systemic anti-infectives, for example, have increased at much lower
rates than have those for sedatives, central nervous system (CNS)
stimulants/antiobesity preparations and psychotherapeutics.2° Be-
cause the elderly are likely to have conditions, diseases, and illnesses
that differ from those of the nonelderly, there is no a priori reason to
expect that the price inflation for the basket of drugs used by the
elderly has occurred at the same rate as that for the drug combinations
used by the nonelderly.
IMS America, a firm specializing in sales and marketing data for
medical and pharmaceutical products, regularly samples the prescrib-
In 1995 (1990), 78.9% (71.8%) of manufacturers' sales were to wholesalers, 12.1%
(15.8%) were to retailers, and 4.8% (9.3%) were to hospitals (Pharmaceutical Research
and Manufacturers of America 1997, fig. 4-12, p. 30).
Indexed to June 1981 = 100, the PPI index values in June 1996 were 145.9, 192.6, and
221.5 for anticoagulants, antiarthritics, and systemic anti-infectives, respectively and
730.9, 605.8, and 500.5 for sedatives, CNS stimulants/antiobesity preparations, and
psychotherapeutics, respectively. (U.S. Department of Labor, Bureau of Labor Statistics,
1996, table 5, p. 61).48 Berndt, Cockburn, Cocks, Epstein, and Griliches
Table 2.5
Twenty top-selling market classes of prescription drugs, by age group, 1996
Under age 65 (81.3% of all mentions)
USC Mentions
code Class name (thousands) Percentage
15100 Broad- and medium-spectrum antibiotics 116,623 15.79
02200 Narcotic analgesics 40,955 5.55
64300 Axthdepressants 34,623 4.69
09100 Systemic aritiarthritics 32,446 4.39
52200 Plain corticoids 28,348 3.84
27100 Biological vaccines 26,593 3.60
28100 General bronchodilators 24,519 3.32
52100 Sex hormones 18,831 2.55
31400 Adrenergic blockers 16,753 2.27
64600 Antianxiety agents 16,611 2.25
31100 Antihypertensives 16,184 2.19
02100 Nonnarcotic analgesics 16,057 2.17
34300 Cough/cold preparation prescriptions 16,000 2.17
28400 Respiratory steroid inhalants 15,000 2.03
23400 Other antispasmodics 14,925 2.02
31700 Calcium channel blockers 14,876 2.01
37400 Fungicides alone/combination 11,993 1.62
34100 Oral cold preparation prescriptions 11,432 1.55
15500 Trimethoprim 11,374 1.54
33200 Oral contraceptives 11,203 1.52
Sum for twenty leading market classes, under age 65 495,346 67.07
65 and over (18.7% of all mentions)
15100 Broad- and medium-spectrum antibiotics 12,616 7.44
31100 Antihypertensives 10,718 6.32
31400 Adrenergic blockers 10,565 6.23
31700 Calcium channel blockers 10,479 6.18
41200 Noninjectable diuretics 8,736 5.15
02200 Narcotic analgesics 7,710 4.55
28100 General bronchodilators 7,268 4.29
09100 Systemic antiarthritics 6,874 4.05
52200 Plain corticoids 6,424 3.79
39200 Oral diabetes therapy 6,337 3.74
23400 Other antispasmodics 5,035 2.97
32100 Cholesterol reducers 4,918 2.90
31500 Digitalis preparations 4,037 2.38
64300 Antidepressants 3,987 2.35
31200 Vasodilators 3,694 2.18Source: National Disease and Therapeutic Index (IlvIS America 1996).
Note: Data were also obtained and analyzed for 1994 and 1992 and yielded similar results.
ing behavior of office-based physicians and publishes the results in the
National Disease and Therapeutic Index (NDTI). Based on an extensive
sample of new prescriptions written by a panel consisting of about
3,000 physicians, information is gathered on, among other matters,
patient age, physician specialty, physician age, diagnosis code, drug
therapy prescribed, concomitant diagnoses, and desired actions; this
sample NDTI data is then projected by IMS to national totals.21
NDTI data therefore permit us to compare the drugs prescribed for
use by the elderly with those prescribed for younger patients, includ-
ing differences involving brands versus generics. Based on annual
NDTI data for 1996 we list, in the top panel of table 2.5, the twenty
top-selling therapeutic classes of drugs for the elderly; in the bottom
panel, we list the corresponding leading classes for the nonelderly.
Prescriptions written for the elderly constitute 18.7% of all new pre-
scriptions, whereas those for the nonelderly account for the remaining
and much larger 81.3%. For both the young and the old, the leading
therapeutic class is broad- and medium-spectrum antibiotics; drugs in
this class comprise almost 15.8% of new prescriptions written for those
under age 65, but only 7.4% for the elderly. The most frequent new
prescriptions for the young include antidepressants, sex hormones,
cough/cold preparations and oral contraceptives; those for the elderly
include various cardiovasculars (antihypertensives, adrenergic block-
ers, calcium channel blockers, diuretics), as well as glaucoma and
cancer therapies. The table does not consider differences between
young and old in the relative use of drugs by therapeutic class; fig-
ure 2.1 highlights the most substantial of these differences. As the
21. For further details, see IMS America 1996, ch. 11. A new prescription refers to a new
script written by the physician and is distinguished from continuing therapy.







61600 Miotics plus glaucoma 3,433 2.02
30200 Other cancer/transplant cytotoxics 3,381 1.99
64600 Antianxiety agents 2,969 1.75
72100 Thyroid hormones 2,430 1.43
61400 Ophthalmic corticoids 2,362 1.39








































CALCIUM CHANNEL BLOCKERS -
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Figure 2.1
1996 NDTI drug mentions by age group and therapeutic class (largest differences
between age groups)
UShare of Class in Mentions
far 65 and Under
O Share of Clans In Mentions
for 65-Is Price Inflation Different for the Elderly? 51
figure shows, the five therapeutic classes with the largest differences
in elderly-nonelderly usage are antibiotics, vaccines, antidepressants,
cough and cold preparations, and oral contraceptives, all of which are
more intensively used by the young.
We now turn to price data. The BLS makes publicly available the
fixed-quantity weights it employs in aggregating the various therapeu-
tic class-specific price indexes into an overall prescription pharmaceu-
tical PPI. The third column of table 2.6 lists these quantity weights from
the BLS's 1993 Cycle C sample; the next column lists the percentage of
all new prescriptions in that therapeutic class that are written for the
elderly. The final six columns list the BLS's PPI by therapeutic class
annually from 1991 to 1996, normalized to 100.0 in 1990.
As shown in table 2.6, the elderly are particularly important consum-
ers in a number of therapeutic classesanticonvulsants (51%), cancer
therapy products (39%), cardiovascular therapy products (42%), diabe-
tes therapy (38%), diuretics (45%), and nutrients and supplements
(53%)although only for the cancer and cardiovascular therapy prod-
ucts are the PPI weights substantial. Therapeutic classes in which the
elderly account for a relatively low fraction of consumption include
systemic anti-infectives (10%), cough and cold preparations (7%), der-
matological preparations (7%), muscle relaxants (8%), and vitamins
(3%). Therapeutic classes with the largest price increases since 1990
include cough and cold preparations (57%), bronchial therapy (54%),
anticonvulsants (48%), systemic antihistamines (45%), and psycho-
therapeutics (45%), and in all cases except anticonvulsants, these are
therapeutic classes with disproportionately large to average use by the
young, rather than by the elderly. Those therapeuticclasses having the
smallest price increases since 1990 include muscle relaxants (16%),
ophthalmic and otic preparations (19%), miscellaneous prescription
pharmaceuticals (21%), antiarthritics (22%), and vitamins (23%); these
show a more mixed pattern of relative usage by old and young.
To aggregate these various therapeutic class PPIs into overall price
indexes separately for the elderly and the nonelderly, we first assume,
for the moment, that within each of the therapeutic classes old and
young face the same prices (an assumption we relax in section IV)and
multiply these BLS therapeutic class quantity weights by the relative
old versus young proportions of 1996 new prescriptions, based on
NDTI data. We then multiply these therapeutic classspecific elderly

















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































9Is Price Inflation Different for the Elderly? 53
Table 2.7
Producer Price Indexes for all pharmaceuticals, those destined for use by the elderly, and
those destined for use by the nonelderly
Note: See text for source and details of procedure for calculation.
class, normalized to unity in 1990.Finally, we aggregate over the
various therapeutic classes and thereby obtain separate prescription
pharmaceutical PPIs for drugs destined for use by the elderly and the
nonelderly. Table 2.7 summarizes results from this calculation over
1990-96.
The very striking conclusion that emerges from inspection of table
2.7 is that in aggregate, manufacturers' prices for pharmaceutical prod-
ucts destined for use by the elderly change at virtually the same rate
as those destined for use by the nonelderly. By 1996, the PPI overall
consumers was 1.330, that for the elderly was 1.331, and that for the
nonelderly was 1.329. Hence, despite substantial differences in usage
among the elderly and nonelderly of drugs from various therapeutic
classes, and even though manufacturers' price changes since 1990 have
varied considerably among the therapeutic classes, in the aggregate, at
the initial point in the distribution chain from drug manufacturers,
there appears to be no price inflation differential by age group, at least
according to the official BLS price statistics.
IV. Retail Sell-In Prices: Elderly versus Nonelderly
The PPI calculations presented in the previous section assume that
within each therapeutic class, prices for products destined for use by
the elderly have the same distribution as those for the nonelderly. We
now relax that assumption.
22. Notice that we are implicitly assuming here that the old-young distribution within
each therapeutic class is the same for sales from manufacturers to wholesalers, to
hospitals, and to retailers. We relax this assumption in section IV.
Year Overall price index Elderly price index Nonelderly price index
1990 1.000 1.000 1.000
1991 1.083 1.083 1.083
1992 1.160 1.163 1.159
1993 1.213 1.211 1.213
1994 1.248 1.247 1.249
1995 1.287 1.284 1.288
1996 1.330 1.331 1.32954 Berndt, Cockburn, Cocks, Epstein, and Griliches
Based on its electronic computer record survey of about 34,000 retail
pharmacies (independents, chains, mass merchandisers, and food
stores), IMS gathers data on brand and generic sales for each chemical
compound as well as on pharmacy acquisition prices and pharmacy
selling prices for the highest selling form/strength/package of each
product. In addition, IMS collects separate retail prices for the top-
selling presentation of each product by method of paymentcash,
Medicaid, and private third party. IMS reports these data in its Retail
Perspective and its Retail Methods of Payment.23
Within each of these three therapeutic classes, data are therefore
available on what drugs were prescribed, whether brand or generic,
the leading seffing form/strength/package of each product, whether
destined for use by the elderly or the nonelderly, sell-in price to
pharmacy, and sell-out prices to consumers and payors. Here we focus
on that point in the distribution chain involving acquisition prices paid
by retail pharmacies (what IMS calls sell-in prices), whereas in section
V we focus on retail pharmacy sell-out prices to various consumers and
payors. We now concentrate on three leading therapeutic classes:
broad- and medium-spectrum antibiotics, calcium chaimel blockers,
and antidepressants.
A priori, two possible hypotheses come to mind concerning differ-
ential elderly-nonelderly drug usage within these therapeutic classes.
The first concerns medications used to treat acute conditions. It is
plausible to assume that the health of seniors is more fragile than that
of the nonelderly and that as a result, prudent medical practice would
advise prescribing for the elderly those products that, given similar
efficacy, had the fewest adverse interactions with other drugs and the
fewest side effects.24 Newly introduced drugs are frequently about as
efficacious as older products but have superior adverse-interaction and
side-effect profiles. More convenient dosing of newer products, such
as once-a-day "sustained release" versions, also facilitates patient com-
pliance, particularly for the elderly, who are more likely to have
memory lapses. These newer products typically command a price
premium and experience greater price inflation than older, off-patent
generic drugs.25 To the extent these assumptions are valid, therefore,
we would hypothesize that for medications used to treat acute condi-
For further details, see IMS America 1996, chaps. 20 and 41.
One might also argue that the very young are more vulnerable as well.
This is clearly the case for antidepressants, such as the selective serotonin reuptake
inhibitors, which have similar efficacy but superior adverse-interaction and side-effectIs Price Inflation Different for the Elderly? 55
tions, prices faced by the elderly would tend to grow more rapidly
than those for the young.26
A second hypothesis concerns medications used to treat chronic
conditions. Here the same basic factors are at work as noted above
for acute conditions. In addition, however, for chronic conditions, the
old might be expected to have chosen to use older drug products,
for physicians are hesitant to change medications when a particular
existing drug regimen is working well.27 With stickier consumption
patterns and by surviving to old age, the elderly would therefore
disproportionally use older drugs, which are more often available as
generics. If this hypothesis is true, drug prices within certain chronic
areas might grow less rapidly for the elderly versus thenonelderly,
because generic prices have fallen in the last decade while prices of
brands typically increased. (See, for example, Griliches and Cockburn
1994 and Berndt, Cockburn, and Griliches 1996.)
However, patent protection has expired for only the very old drugs.
For older drugs still patent protected, price increases tend to be larger
than for younger drugs. (See, for example, Berndt, Griiches, and
Rosett 1993; Kanoza 1996; and Ristow 1996.) Thus, any price inflation
differential between old and young consumers of both acute and
chronic medications depends on the distribution of sales between older
drugs with and without patent protection. Because such a distribution
is an empirical matter that could vary by therapeutic class and change
over time, our hypotheses make no definitive predictionfor any eld-
erly-nonelderly price inflation differential but must be examined in the
context of the distribution of sales between brands and generics in each
therapeutic class.
Among the three therapeutic classes we examine here, we expect
that the cardiovascular products, such as calcium channel blockers, are
used predominantly for treatment of chronic conditions, whereas the
broad- and medium-spectrum antibiotics are used primarily to treat
acute conditions. In terms of protracted use, antidepressants are most
likely to fall between the antibiotics and the cardiovasculars, because
they are used to treat both episodic and more chronic forms of de-
pression. In all three therapeutic classes, however, the elderly and
proffles relative to the older tricyclic antidepressants. See Berndt, Cockburn, and
Griliches 1996 for further discussion.
For a discussion of pricing considerations involving drugs to treat acute versus
chronic conditions, see Lu and Comanor 1996.
This is consistent with the common medical adage, "Don't shoot a singing bird."56 Berndt, Cockburn, Cocks, Epstein, and Grffiches-
nonelderly may use drugs for a different set of conditions. In the case
of antidepressants, for example, physicians frequently prescribe tricy-
dc antidepressants for "off-label" conditions, such as chronic pain
syndromes, that the elderly experience more frequently.
With this as background, we begin by examining retail pharmacy
acquisition (sell-in) costs and price indexes for the broad- and medium-
spectrum antibiotic (AB) class of drugs. As the top panel of table 2.8
shows, retail acquisitions of ABs almost doubled from 1990 to 1996,
growing from $2.1 to $3.8 billion. Roughly 90% of the retail pharmacy
acquisition costs are for ABs destined for use by the young. The overall
brand/generic shares for ABs are somewhat volatile, ranging from
81%/19% in 1990 to 90%/10% in 1993. Over the entire time period,
brand share for the elderly has grown from 82% to 91% (generic share
has fallen from 18% to 9%), whereas for the young, the brand share has
increased only from 81% to 87%. The AB brand share hit its peak in
1992-94 at about 89-90% (for all), then fell to about 88% (all), 87%
(young) and 91% (elderly) in 1996. Thus, particularly since 1992-94, the
elderly's use of branded antibiotic products has grown considerably
more rapidly and to greater proportions than that of the young. This
is, of course, consistent with the acute-care hypothesis discussed
above. It is also consistent with the notion that the elderly are increas-
ingly using newer, branded products having higher efficacy in treating
severe or life-threatening infections such as pneumonia, in part be-
cause of increasing bacterial resistance to older drugs.28
We now turn to price indexes, which can be constructed in a number
of ways. The BLS employs a fixed-weight procedure known as the
Laspeyres price index that keeps weights of the various items in the
index fixed over time. The CPI commission has criticized this fixed-
weight procedure and has recommended instead a chain-weighted
index with changing weights that reflect evolving market shares of
items over time. (See U.S. Finance Committee 1996.) The most common
version of such a chained index is the (Tornqvist discrete approxima-
tion to the) Divisia index.29 We therefore construct price indexes mim-
Successful brands introduced since 1990 with substantial use by the elderly include
Floxin and Lorabid. Sales of other, older brands such as Ceftin and Cipro (introduced
in 1987) have also grown substantially.
The fixed-weight Laspeyres price index is calculated asLtZipjtqo/Z1poqo,where
Piti5 the price of item i in period t, pçj is the base period price, and qio is the base period
quantity. The Tornqvist discrete approximation to the Divisia index is calculated asDt
exp[zjt(in Pit -inPi,t - i)]Dt -i, where .5*(cojt + 'm,t-i) andoitptqt/Z,ptqt,
and wereD0is normalized to unity in the base year.Is Price Inflation Different for the Elderly? 57
icking the BLS fixed-weight procedure, using 1990 fixed-quantity
weights, but also report price indexes with the more preferred Divisia
index calculation that allows for changing market shares.3°
In rows labeled "Laspeyres" in the top panel of table 2.8, we present
1990-96 retail acquisition price indexes for ABs over all consumers
(Laspeyres indexAll), for ABs destined for use by the young (Young)
and for ABs destined for use by the old (Elderly).31 We first obtain the
somewhat surprising result that with the Laspeyres index, over the
entire 1990-96 time period, ABs used by the elderly increased in price
about 12%, whereas for the nonelderly the price increase was some-
what larger, at 17%. However, if one looks only from 1992 onward, the
reverse occurredthe elderly AB price index increased 11 %, from
1.009 to 1.121, whereas that for the nonelderly increased 7%, from 1.096
to 1.173.
These findings for ABs are essentially unaffected when one employs
changing share weights and the preferable Divisia index.32 As seen in
the bottom three rows of the top panel of table 2.8 and graphically in
figure 2.2, using the Divisia, by 1996 the price index for ABs destined
for use by the elderly was 1.07, slightly less than the 1.11 for the young.
After 1992, however, the AB price index increased only very slightly
for the young (2% from 1.08 in 1992 to 1.11 in 1996), whereas for the
elderly it increased considerably more (7%, from 1.00 to 1.07). In part,
this old-young differential reflects a greater increase in use of newer
branded drugs by the old than by the young since 1992, as noted
above. To show this in greater detail, in figure 2.3 we present 1996
elderly utilization for each AB molecule and distinguish brands (light
bars) from multisource (dark bars) drugs. The dotted vertical line in
figure 2.3 represents the elderly average percentage over all ABs
(9.8%). The elderly's differential use of brands and generics can be seen
by noting that for the vast majority of drugs involving relatively
This fixed-weight procedure is not the same as that employed by the BLS in its CPI
for prescription drugs for a number of reasons, including the fact that the CPI uses only
OOPs' weights, whereas weights here include retail acquisition costs for products des-
fined for payment by cash, third party and Medicaid. Moreover, the index here refers
to retail acquisition costs, not retail sales to patients and payors. Cleeton, Goepfrich, and
Weisbrod (1992) and Armknecht, Moulton, and Stewart (1994) describe the BLS's CPI
method for prescription drugs.
The elderly-nonelderly split for each drug is based on the average of the 1992, 1994,
and 1996 NDTI values.
For the Laspeyres, the number of AB items is fixed at 156, whereas for the Divisia,
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Figure 2.2
Divisia price indexes for antibiotics ("sell in" prices to retail pharmacies)
Source: IMS Retail Audit, IMS NDTI, authors' calculations.
intense use by the elderly, the molecule in question is a branded,
single-source (light bar) drug.
We now turn to retail sell-in prices for antidepressants (ADs). As the
top row of the middle panel of table 2.8 shows, retail-sector purchases
of ADs surged by a factor of about four between 1990 and 1996, thereby
growing considerably more rapidly than those of ABs, although by
1996 total retail acquisition expenditures for the two were about equal,
at $3.73 billion for ADs versus $3.77 billion for ABs. ADs were also
similar to ABs in that the retail acquisition dollar share for products
destined for use by the young for both classes was about 90%, with a
very slight upward trend over the period. A distinctive feature of the
AD market involves the tremendous growth in sales of the newest
generation of ADs, the selective serotonin reuptake inhibitors (SSRIs)
such as Prozac, Zoloft, Paxil, Luvox, and Serzone. This high growth of
new branded products has resulted in a sharply declining generic
dollar share of retail-sector purchases (from 12% in 1990 to 3% in 1996)
and a corresponding increase in the dollar share for brands (88% to
97%). In each year between 1990 and 1996, the share of retail drugstore
purchases of generic ADs for use by the elderly was larger than that
for the young; the 1990 generic shares for old and young were 15% and
















































Share of 1996 NDTI mentions for age 65+ patients: Antibiotics
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Figure 2.4
Divisia price indexes for antidepressants ("sell iiprices to retail pharmacies)
Source: IMS Retail Audit, IMS NDTI, authors' calculations.
tively. This differential brand-generic pattern could reflect the phe-
nomenon noted above that certain generic tricycic antidepressants are
often prescribed "off-label" to treat chronic pain syndromes that occur
more frequently in the elderly.
With respect to price indexes, we first report results based on the
fixed-weight Laspeyres procedure. As shown in the middle panel of
table 2.8, the AD price inflation differential between old and young
appears to be negligibleby 1996, the Laspeyres index for the elderly
was 1.30, very slightly less than that for the young at 1.32.
For the more appropriate Divisia index, which takes changing shares
into account, however, the inflation differential is considerably larger,
with the 1996 index being 1.20 for the elderly but 1.28 for the young.33
In figure 2.4 we plot these Divisia AD price indexes for the entire
population, for the elderly, and for the young. As the figure shows,
price inflation for retail acquisitions of ADs destined for use by the
elderly has been appreciably less than that for ADs destined for use by
the young.
To understand the reason underlying this inflation differential, in
figure 2.5 we plot the elderly share for each AD chemical molecule; the
patent-protected drugs are again marked with light bars, and generic
33. The number of items in the 1990 fixed weight Laspeyres index is 46, whereas for the
Divisia it is 50 in 1990-1, 54 in 1992-3, 58 in 1994-5, and 60 in 1996.
62 Berndt, Cockburn, Cocks, Epstein, and Grffiches0% 5% 10% 15% 20% 25% 30% 35%
Figure 2.5
Share of 1996 NDTI mentions for age 65 patients: Antidepressants
Source: IMS NDTI and authors' calculations.
or multisource drugs are marked with dark bars; overall AD mole-
cules, the elderly average share is 10.3%, represented by the dotted
vertical line. As the figure shows, the elderly's use of off-patent and
generic drugs such as trimipramine, protriptyline, nortriptyline,
maprotiline, imipramine, doxepin, amoxapine, and amitriptyline is
above that of the general population. Elderly use of some newer and
still patent-protected branded drugs such as venlafaxine (brand name
Effexor), sertraline (Zoloft), paroxetine (Paxil), and nefazodone (Ser-
zone) is about the same as that of the general population, but elderly
use of other patent-protected ADs such as fluvoxamine(Luvox),
fluoxetine (Prozac), and buproprion (Weilbutrin) is less than that by
the general population. Given these differential brand-generic uses by
the elderly versus the young, and with generic prices faffing while
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brand prices are increasing, the basket of ADs destined for use by the
elderly is increasing more slowly in price than the basket of ADs
destined for use by the young. Because it employs changing share
rather than fixed weights, the Divisia index better captures these
dynamics. Note that the inflation differential would be even larger if
the dollar share of generics had not been falling.
Next we turn to the calcium channel blockers (CCBs), drugs used to
treat cardiovascular conditions, which have brand names such as Card-
izem, Norvasc, and Procardia XL. As with the ABs, acquisition costs of
CCBs among retailers approximately doubled from 1990 to 1996, with
total acquisition costs of around $3.2 billion in 1996, about 15% less
than for ABs. The elderly share of CCBs, however, is much larger than
that for ABs and ADs. As the bottom panel of table 2.8 shows, the retail
acquisition dollar share of CCBs for the elderly is more than 40%,
having fallen slightly from 45% in 1990 to 42% in 1996. The brand-
generic market share pattern is also different, and is not monotonic
over time, reflecting in part episodic patent expirations and generic
entry within the 1990-96 time frame. For the elderly, the generic share
increased from 1% in 1990 to 8% in 1994, then fell to about 4% in 1996;
for the young, the respective generic shares are similar, at 2%, 8%, and
4% for those same years, respectively.
In terms of price indexes, because of the relatively small brand-
generic differences by age group, there is only a negligible difference
between CCB retail-acquisition price inflation for products destined for
use by the elderly versus those for the young. Specifically, as shown in
the bottom panel of table 2.8 and graphically in figure 2.6, the old-
young Laspeyres indexes are 1.27 versus 1.26, whereas for the Divisia
they are 1.11 versus 1.10. In large part, this similarity in elderly-
nonelderly price inflation for CCBs reflects the fact that brand-generic
differences between the old and young are much smaller in any given
year for the CCBs than they are for the ADs and ABs. Figure 2.7
displays this more modest relative variability for each of the CCB
chemical molecules. Variations in elderly-nonelderly differences, other
than for bepridil (brand name Vascor) and nimodipine (Nimotop), are
modest.
In summary, therefore, over the entire 1990-96 time period, retail-ac-
quisition price inflation for antidepressants destined for use by the
elderly has been less than that for the young, reflecting the elderly's
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Figure 2.6
Divisia price indexes for calcium channel blockers ("sell in" prices to retail pharmacies)
Source: IMS Retail Audit, ilviS NDTI, authors' calculations.
erably greater since 1992 for antibiotics used by the elderly, but the
differential is much smaller over the entire 1990-96 time period. More-
over, for antibiotics, the greater elderly price inflation since 1992 ap-
pears to reflect the more rapid growth in the elderly's use of the
newest, branded drugs, for which bacterial resistance is less. For cal-
cium channel blockers, however, the elderly-nonelderly inflation dif-
ferentials are negligible.
Two other general results are worth noting. First, growth over time
in the sell-in prices for all three therapeutic classes based on the IMS
data employed here is less than the inflation as measured by the BLS's
producer price index, even when employing the Laspeyres procedure;
the 1990-96 differences here are 1.29% per year for ABs, 1.61% for ADs,
and 0.83% for CCBs.34 This differential could reflect different pricing
for leading (best-selling) presentations of drugs (the IMS data) than for
the basket examined by the BLS, but it could also reflect a known BLS
bias in oversampling older branded drugs. (For further discussion, see
34. These differences are computed as growth in the BLS's PPI by therapeutic class
(systemic anti-infectives for ABs, psychotherapeutics for ADs, and cardiovasculars for
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Figure 2.7
Share of 1996 NDTI mentions for age 65+ patients: Calcium channel blockers
Source: IMS NDTI and authors' calculations.
Berndt, Cockburn, and Griliches 1996; Berndt, Griliches, and Rosett
1993; IMS America 1996; and Kanoza 1996.)
Secondly, as shown in table 2.8, in each case the fixed-weight Las-
peyres price index yields a larger measure of price inflation than does
the corresponding Divisia index. Over all consumers, for example, the
difference is 0.92% per year for ABs, 0.65% for ADs, and 2.34% for
CCBs. If one sums these two differentials, the differences in average
annual growth rates between the BLS's PPI and the Divisia for retail
acquisition prices is 2.21% for ABs, 2.26% for ADs and 3.17% for CCBs.
These results are therefore quite consistent with other findings re-
ported by the CPI commission and emphasize the importance of the
recommendations the commission made, particularly those involving
use of changing versus fixed weights.
V. Retail Sell-Out Prices: Elderly Versus Nonelderly
We now examine price growth in the final point of the distribution
chain, that from retail pharmacies to patients and payors. Our research
here must be viewed as preliminary in at least two respects. First, we
have been unable to obtain reliable method-of-payment data that sepa-
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rates cash, Medicaid, and third-party insurance payment for the eld-
erly and the nonelderly since 1991. Data graciously made available to
us involving a third-party insurer implied an implausibly huge decline
in the elderly's use of cash as a method of payment. Our inability to
obtain reliable national data is unfortunate, for casual empiricism
suggests to us that the elderly's use of third-party payment arrange-
ments to pay for drugs has increased more rapidly in the last few years
than that of the general population, particularly because the retired
have moved into "Medigap" managed-care arrangements that offer
prescription drug benefits. If in fact in recent years seniors have moved
to third-party drug payment more rapidly than the young (consistent
with the OOPs data in table 2.3) and therefore increasingly are less
affected by higher cash prices, then seniors are disproportionately
availing themselves of lower managed-care prices, resulting in lower
drug price inflation (but perhaps still higher average price levels) than
that experienced by the nonelderly. Research on this issue must be
postponed until appropriate data become available.
Second, the IMS sell-out methods-of-payment data are based on the
best-selling presentation of a particular branded or generic drug. Prob-
lems emerge in measuring price and quantity changes consistently
over time when these leading presentations change for brands, and
even more so for specific generic manufacturers, over the time period
under consideration. These problems are particularly evident in our
data involving the antibiotics and calcium channel blockers, as are
related problems involving products embodying combinations of
chemical molecules. In the future we will be working with IMS to
obtain data on additional presentations for branded and generic
chemical molecules as well as information involving the combination
products.
For antidepressants, fortuitously, this second problem involving
leading presentations turns out essentially not to be an issue. Thus we
report here our preliminary findings on sell-out prices by retail phar-
macies for only the antidepressant class of prescription drugs. More-
over, because reliable method-of-payment data distinguishing among
cash, Medicaid, and third party are not yet available for the elderly and
the nonelderly, here we simply employ a weighted average of prices
among the three payment methods, assuming the weights in table 2.1
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IMS method-of-payment data are available only since 1991, whereas
the sell-in data analyzed in the previous section go back to 1990. We
therefore begin by renormalizing the AD sell-in data from table 2.8 so
that the Divisia price index for the AD drugs is 1.000 in 1991. The upper
left panel of table 2.9 presents the results of that renormalization. As
the table shows, from 1991 to 1996, sell-in prices for AD drugs destined
for use by the elderly increased 12%, whereas sell-in prices for AD
drugs destined for use by the young increased 19%.
In the introduction to this chapter, we noted the dramatic change
over time in retail methods of payment, away from cash and toward
third-party payor. For retail pharmacies, the growth in third-party
payment implies dealing with a more organized and powerful
buyer/payor than is the typical cash customer. We therefore expect
that over this time period, sell-out prices (the sum of copayments and
third-party reimbursements received by the retail pharmacies) have
increased less rapidly than have sell-in prices. One very simple way of
highlighting this difference is to compute a "gross margin index,"
defined as the sell-out price index divided by the sell-in price index,
the former incorporating data from table 2.1 on changing methods of
payment over time, assumed to be the same for ADs as for all drugs.
In the top right panel of table 2.9, we present the Divisia price index
for retail sell-out, normalized to unity in 1991, and in the bottom panel
we list the gross margin index, constructed as outlined in the previous
paragraph. Two results are particularly interesting.
First, as expected, the increased role of third-party payors since 1991
has pressured pricing downward in the retail pharmacy sector; al-
though AD prices on a sell-in basis increased 18% over all customers
from 1991 to 1996, corresponding sell-out prices increased only 14%.
Thus, gross margins for retail pharmacies selling AD products fell 3.5%
from 1991 to 1996.
Second, this declining gross margin primarily involved sales of ADs
to the young, for whom sell-in retail acquisition prices increased 18.8%
from 1991 to 1996 while sell-out prices increased 14.2%, implying a
decline of 3.8% in gross margins. For the elderly, however, the gross
margin hardly declined at all; indeed, it increased very slightly, 0.4%.
One reason for this disparity is that, as noted earlier and shown
visually in figure 2.5, the elderly are disproportionately large consum-
ers of generic AD drugs. A number of studies have documented that
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Table 2.9
Divisia retail sell-in and sell-out price indexes for antidepressants
Gross margin index (Sell-out/Sell-in)
Note: Sell-out is in dollars per daily dose of leading presentation, weighted average over
channels, with the same channel weights for old and young.
age terms, but often also in absolute amounts, than that on branded
products (see, for example, the Federal Trade Commission study by
Masson and Steiner (1985) as well as Caves, Whinston, and Hurwitz
1991); that turns out to be the case here as well.35 One implication of
this larger generic retail margin along with disproportionately large
elderly use of generics is that retail pharmacy margins have been
under greater downward pressure from nonelderly customers than
from the elderly. It must be emphasized, however, that these calcula-
tions in table 2.9 assume that the method-of-payment trends displayed
in table 2.1 are the same for ADs as over all drugs, and the same for
the elderly and the young. If in fact the elderly are moving into
35. For one well-known branded selective serotonin reuptake inhibitor, for example, the
sell-in price in 1996 was $1.71, but the sell-out price averaged over method-of-payment
channel was $2.06, implying a $0.35 absolute margin and a 20.5% percentage gross
margin [(sell-out/sell-in) -1]. By comparison, for one well-known older generation
txicycic antidepressant, the sell-in price was $0.12, and the sell-out price was $0.54,
implying a $0.42 absolute margin and a 350% percentage gross margin. Note that one
would expect the percentage margin to be larger for generics, because a common
dispensing fee is added to a lower generic acquisition price.
Year
Sell-in Divisia price index Sell-out Divisia price index
Young Elderly Total Young Elderly Total
1991 1.000 1.000 1.000 1.000 1.000 1.000
1992 1.085 1.079 1.084 1.075 1.073 1.075
1993 1.104 1.089 1.102 1.083 1.076 1.082
1994 1.110 1.064 1.105 1.081 1.073 1.080
1995 1.136 1.076 1.130 1.114 1.096 1.112
1996 1.188 1.116 1.181 1.142 1.121 1.140
Year Young Elderly Total
1991 1.000 1.000 1.000
1992 0.990 0.994 0.992
1993 0.981 0.988 0.982
1994 0.974 1.008 0.977
1995 0.980 1.018 0.984
1996 0.962 1.004 0.96570 Berndt, Cockburn, Cocks, Epstein, and Griliches
third-party payment arrangements for drugs more rapidly than the
young, these gross margin differentials between young and old tend
to be overstated.
VI. Summary and Issues for Further Research
Our purpose in this chapter has been to examine whether prescription
drug price inflation in the 1990s has differed between the elderly and
the nonelderly when prices are viewed at three alternative points in
the distribution chain. Our first finding is that in the aggregate, over
all therapeutic classes of prescription drugs, we find essentially no
age-related price inflation differential at the initial point in the distri-
bution chain involving manufacturers' sales to wholesalers, retailers,
and hospitals.
At an intermediate point in the distribution chain involving acquisi-
tion prices of retail pharmacies for purchases from manufacturers and
wholesalers, we examined sell-in prices for three therapeutic classes of
pharmaceuticals, antidepressants, antibiotics and calcium channel
blockers over 1990-96. Here we observed some elderly-young price
inflation differentials. Specifically, we found that from 1990 to 1996, the
Divisia price index for ADs destined for use by the elderly grew at an
average annual growth rate (AAGR) of 3.10%, whereas that for ADs
destined for use by the young grew at a higher AAGR of 4.19%. The
source of the elderly's lower inflation rate was their disproportionately
greater use of older and generic drugs, whose prices are typically
falling, whereas those of newer and branded ADs are generally
increasing.
For ABs, we observed a slightly different set of trends. Over the
entire 1990-96 time period, the Divisia price index for ABs destined for
use by the elderly grew at an AAGR of 1.17%, again somewhat less
than the 1.74% for those destined for use by the young. Since 1992,
however, the elderly price index for ABs has grown at an AAGR of
1.88%, considerably more than the 0.59% for the nonelderly. This
difference appears to arise from a more rapid growth among the
elderly in the use of the newer, branded drugs than among the young,
particularly since 1992. One interpretation of this apparent price infla-
tion differential is that the more fragile elderly are disproportionately
using the newer antibiotics that have not yet developed bacterial
resistance, when being treated for severe or life-threatening infections
such as pneumonia.Is Price Inflation Different for the Elderly? 71
Finally, for the calcium channel blockers, the elderly-young sell-in
price inflation differential was found to be negligible, with AAGRs
being 1.60% for the young and 1.77% for the elderly.
The final point we examined in the distribution chain involves sales
of retail pharmacies to consumers and payors. Because of data limita-
tions, we were able to compute sell-out price indexes only for the
antidepressant class of prescription drugs. The dramatically increasing
share of prescriptions paid for by third-party insurance since 1991 has
resulted in retail pharmacy sell-out prices for ADs increasing less
rapidly than sell-in prices. The retail pharmacy gross margin index
over all customers appears to have fallen about 3.5% between 1991 and
1996, with young patients enjoying most of the benefits of this in-
creased power of managed care over time at the expense of the retail
pharmacy sector. For the elderly, the retail gross margin on ADs has
not fallenindeed it has risen very slightly, reflecting in part the fact
that the elderly are disproportionately large users of generic ADs,
along with the previously documented finding that retail margins on
generics tend to be larger than those on branded products. Our sell-out
and gross margin calculations assume that trends in methods of pay-
ment among cash, Medicaid, and third-party payors are the same for
the elderly and the young. To the extent that recently the elderly are
enrolling in third-party arrangements with drug benefits at a more
rapid rate than the young, this gross margin differential tends to be
overstated, as does growth in sell-out prices for the elderly.
One useful extension of our empirical analysis would involve the
introduction of mail-order data into our analysis. Although mail-order
sales currently account for only about 9% of all prescription drug sales
dollars, mail order is a rapidly growing segment, and apparently one
in which the elderly are disproportionately represented.36 Excluding
mail-order prescription drug sales from our analysis most likely results
in our overstating overall price growth for the elderly.
In this chapter we have made no attempt to adjust estimated price
inflation differentials for variations in the quality of the products used
by the elderly versus the young, nor have we linked prices of generics
at entry with previous prices of their patented antecedents. It is possi-
ble, of course, that our findings on greater elderly AB price inflation
relative to the young and smaller elderly AD price inflation when
36. Data made available to us involving one mail-order firm showed that more than half
the prescriptions it dispensed were mailed to patients 65 years and older.72 Berndt, Cockburn, Cocks, Epstein, and Griliches
compared to the young could be entirely reversed were quality adjust-
ments taken into account. Adjusting price changes and price differen-
tials for quality changes is therefore an important issue meriting
further research.
One clear finding emerging from this research and corroborated in
other studies cited by the CPI commission is that the use of a fixed-
weight Laspeyres price index procedure, such as that employed by the
BLS, yields price indexes whose growth is misleading and distorted. In
particular, for all three classes of drugs studied, and for all groups of
customers, price growth as measured by the Laspeyres fixed-weight
procedure (as employed by the BLS) resulted in greater measured
inflation than the market share chain-weighted Divisia index. This
finding is consistent with that of other studies cited in the CPI commis-
sion's report and emphasizes the importance of their finding concern-
ing the upward bias of the Laspeyres index and their recommendation
of moving to a changing-weight index.
Finally, in this chapter we have examined inflation price differentials
involving the elderly and the nonelderly, implicitly assuming that the
elderly are homogeneous. It is possible, of course, that there are more
differences within the elderly than there are between the elderly and
the young. Is income or expenditure inequality greater among the
elderly than between the young and elderly? Are there more children
living in poverty than there are elderly living solely on Social Security?
Clearly, formulating appropriate public policy involving the elderly
depends in part on the within versus between issue involving the
elderly.37 In a somewhat different context involving other products,
Robert Michael (1979) reports greater variation in expenditures within
various demographic groups than between them. Examining the vari-
ability in health expenditures and in price inflation for health-related
items within the elderly demographic group is therefore also a topic
worthy of further attention. (See recent unpublished 'research findings
by David Cutler and Elizabeth Richardson (1997) and Angus Deaton
and Christina Paxson (1997).
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